Thursday, 7 July, 2022
HomeIndiaScientists at CCMB in Hyderabad develop new mRNA technology-based COVID-19 vaccine candidate

Scientists at CCMB in Hyderabad develop new mRNA technology-based COVID-19 vaccine candidate

Text Size:

Hyderabad, May 13 (PTI) Hyderabad-based CSIR-Centre for Cellular and Molecular Biology (CCMB) on Friday announced the development of a potential mRNA vaccine candidate against SARS-CoV-2.

The mRNA vaccine technology so developed, is indigenous and devoid of any technology contributions from elsewhere, it said in a release.

The team at the Atal Incubation Centre-CCMB (AIC-CCMB) led the development of the vaccine candidate.

mRNA vaccines are among the leading vaccine technologies today. The world witnessed the power of the first mRNA vaccines during COVID-19 pandemic, it said.

Vaccines work by training our immune system to identify disease-causing micro-organisms and eliminate them quickly when they encounter them subsequently.

mRNA vaccine technology does this by introducing an mRNA of the micro-organism of concern.

This mRNA in the host cells gives rise to the microbial protein or a part of it, which trains the immune system to evade it when the real infection happens with the same live micro-organism, it said.

The CSIR-CCMB is leading the development of mRNA vaccine technology in the country.

“We observed robust immune response against SARS-CoV-2 Spike protein in mice, upon administration of two doses of the mRNA. The anti-spike antibodies generated were found to be more than 90 per cent efficient in preventing the human ACE2 receptor binding to the coronavirus,” said Rajesh Iyer, scientist involved in the project.

Currently, the mRNA vaccine candidate is undergoing pre-clinical challenge studies to evaluate its efficacy to protect against live virus infection, the release said.

“The current war with COVID-19 pandemic had brought to light many vaccine technologies, and India’s vaccine programme is highly lauded. However, we lacked the potent mRNA vaccine technology, as developed by Moderna or Pfizer/BioNtech to combat COVID-19 in the USA and Europe,” said Madhusudhana Rao, CEO, AIC-CCMB and the lead scientist of the work.

“The developed technology is different from mRNA vaccine being developed from Gennova Bio, which is based on self-replicating RNA,” Rao said.

He added that the AIC-CCMB team was able to establish mRNA vaccine technology and develop a home-grown mRNA vaccine candidate against SARS-CoV-2 in less than a year since the inception of the project.

Even though COVID-19 is waning, the vaccine platform holds promise for many infectious diseases that India faces, the release said.

“This a proof-of-principle wherein we have shown that we can replicate the mRNA vaccine technology end-to-end. The beauty of this technology is in its modularity and rapid turn-around times. That means with significantly less efforts, the developed technology can be used to sire vaccine for other infectious diseases like dengue, tuberculosis or malaria,” said Vinay Nandicoori, Director of CCMB. PTI SJR HDA

This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular

×